A new generic competitor for the popular allergy drug EpiPen isn’t going to be any cheaper than one already on the market, even though the Trump administration touted the generic as evidence its fight against high drug prices was working.

Teva Pharmaceuticals announced on Monday it will provide its generic version of the EpiPen in limited doses for $300. The price is the exact same as one already on the market made by Mylan, the original brand-name maker of the EpiPen.